Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term luseogliflozin plus amino acid supplementation with intensive exercise in elderly type 2 diabetes mellitus
jRCTs041210048Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in HbA1c. Started Aug 2021; status: recruiting.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs041210048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210048.